These aggravating factors are all associated with the use of RAAS blockers, which—together with the increased expression of ACE2 induced by these drugs—suggests that the use of RAAS blockers (particularly ACE inhibitors) could be a risk factor for disease severity and poor prognosis in patients with COVID-19.[10,11] Nonetheless, there is some evidence to suggest that ARBs could protect against lung injury in COVID-19.[8] Clearly, there are many open questions and controversies surrounding the effect of these and other medications on the course of disease in patients with COVID-19.[11]. The gene discussed is ACE2; the disease is COVID-19.